Features Of The Clinical Course Of Complicated Forms In Patients With Migraine (Migraine Status), Concomitant Hypertension, Ways Of Drug Correction

Authors

  • Sanoeva M.J.

DOI:

https://doi.org/10.47750/pnr.2022.13.S09.577

Abstract

The widespread prevalence of migraine and its negative impact on the quality of life determine the urgency of the problem. The aim of the study was to study the features of the clinical course of complicated forms in patients with migraine (migraine status), concomitant hypertension, to optimize the ways of their drug correction. 325 patients (100%) aged 26 to 46 years (mean 42.4±2.8 years) were examined, of which 58 (17.8%) patients with migraine status, comorbid with hypertension; 64 (19.7%) patients with migraine status, without hypertension; 111 (34.2%) patients with uncomplicated migraine, without a combination of hypertension; 92 (28.3%) patients with hypertension, without a combination of migraine. Clinical neurological, neuropsychological (HDRS- 21, HAM-A, M.P. Kononova's method, "RAM", A.R. Luria's method; three-dimensional pain intensity scale – NRS, VRS, VAS; IRLS0 evaluation scale; polysomnography (PSG), electroneuromyography (ENMG) were used. Standard migraine therapy, antihypoxants and antihypertensive drugs were used to correct clinical symptoms. When complicated forms of migraine are combined with hypertension, clinically pronounced depression, anxiety, restless legs syndrome are noted. Hypertensive comorbid disease with migraine leads to deterioration of neurocognitive, vascular, perfusion abilities of the brain. A differentiated approach to diagnosis, treatment and correction reduces the intensity and frequency of migraine attacks, improves the neuropsycho pathological condition and vascular component of the disease.

Downloads

Published

2022-12-08 — Updated on 2022-12-08

Versions

Issue

Section

Articles

How to Cite

Features Of The Clinical Course Of Complicated Forms In Patients With Migraine (Migraine Status), Concomitant Hypertension, Ways Of Drug Correction. (2022). Journal of Pharmaceutical Negative Results, 4651-4653. https://doi.org/10.47750/pnr.2022.13.S09.577